Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, Oct. 30, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. 

Upwind boosts its valuation to $3.8 billion

Kristen Scholer delivers the pre-market update on October 30th

• OPay will begin trading on the NYSE under the ticker symbol 'OPAY.'
  • The firm's IPO gives it a market cap above $4 billion.
  • NYSE Live will have extensive coverage of the celebration, including executive remarks and an interview with Co-CEO Lars Boilesen.
  • Connor Group Managing Partner Jim Neesen will deliver his latest insights on the current IPO market.
• Upwind raises $400 Million in Series C funding   
  • Upwind says the capital will boost its product and engineering growth.
  • The company's latest round of funding comes less than nine months after it raised $250 million in a Series B round.
  • Co-founder + CEO Amiram Shachar will join Taking Stock to discuss how the funds will help defenders protect new risks in the AI era.
• Adobe becomes official AI Fan Experience Partner for the BWT Alpine Formula One Team
  • The company says it plans is to give fans tools to create and share their own content with AI
  • Adobe expands its global partnerships across other pro sports leagues including the NFL, MLB, and NHL. 
  • Adobe executive Marissa Dacay will join NYSE Live to elaborate on the company's strategy in the sports ecosystem.

• The firm's IPO gives it a market cap above $4 billion.
• NYSE Live will have extensive coverage of the celebration, including executive remarks and an interview with Co-CEO Lars Boilesen.
• Connor Group Managing Partner Jim Neesen will deliver his latest insights on the current IPO market.

• Upwind says the capital will boost its product and engineering growth.
• The company's latest round of funding comes less than nine months after it raised $250 million in a Series B round.
• Co-founder + CEO Amiram Shachar will join Taking Stock to discuss how the funds will help defenders protect new risks in the AI era.

• The company says it plans is to give fans tools to create and share their own content with AI
• Adobe expands its global partnerships across other pro sports leagues including the NFL, MLB, and NHL. 
• Adobe executive Marissa Dacay will join NYSE Live to elaborate on the company's strategy in the sports ecosystem.

Opening Bell
OPay (NYSE: OPAY) celebrates its IPO

Closing Bell
The WLDA Summit rings the Closing Bell

For market insights, IPO activity, and today's opening bell, download the NYSE TV App and check out the NYSE YouTube: TV.NYSE.com and YouTube.com/@NYSEofficial

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update

BOSTON, , Oct. 31, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration.

A Three-Year Partnership Built on a Trusted R&D Model

Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO–client collaboration.

At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed "undruggable"—and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership.

In-Depth Discussions Explore New Collaboration Opportunities

During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency.

Laboratory Tour

Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"